Health
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson’s disease will be presented in a Guided Poster Tour session at the 30th World Congress
About this update from Biovie Inc.
[{"type":"image","alt":"BioVie, Inc.","displaySize":"","headline":null,"caption":"BioVie, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/74wuLVBY92R9d2c1AJ.QhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a","width":300,"height":79}},"lazy":false},{"type":"text","content":"CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson’s disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City.","length":608,"tagName":"p"},{"type":"text","content":"Details for the presentation are as follows:","length":44,"tagName":"p"},{"type":"text","content":"Title: Assessment of Bezisterim (NE3107) in Patients with Early Parkinson’s Disease: A Phase 2, Placebo-Controlled, Hybrid Decentralized StudyPresentation date and time: Saturday, May 10Presentation time: 8:00-9:00am EDTPresenter: Joseph M. Palumbo, MD, Executive Vice President, Head of Research & Development and Chief Medical Officer, BioVie Inc.","length":356,"tagName":"p"},{"type":"text","content":"SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design that will last 20 weeks from the initial screening phase to the safety follow up.","length":206,"tagName":"p"},{"type":"text","content":"As part of the trial, patients may participate either completely from their home or at a clinical site. At-home participants will be visited by study nurses who will complete study assessments with the assistance of a neurologist who will attend the visit remotely by video and supervise administration of a modified MDS-UPDRS Part III examination, which will be recorded for review and scoring by a central rating committ...